Jazz Pharmaceuticals PLC (JAZZ)vsRegeneron Pharmaceuticals Inc (REGN)
JAZZ
Jazz Pharmaceuticals PLC
$238.57
-0.62%
HEALTHCARE · Cap: $14.48B
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.46%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 236% more annual revenue ($14.92B vs $4.44B). REGN leads profitability with a 29.6% profit margin vs 0.7%. JAZZ appears more attractively valued with a PEG of 0.96. REGN earns a higher WallStSmart Score of 64/100 (C+).
JAZZ
Buy56
out of 100
Grade: C
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+52.2%
Fair Value
$347.46
Current Price
$238.57
$108.89 discount
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Strong operational efficiency at 23.5%
19.1% revenue growth
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
3.2% earnings growth
ROE of 0.7% — below average capital efficiency
0.7% margin — thin
Elevated debt levels
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : JAZZ
The strongest argument for JAZZ centers on PEG Ratio, Operating Margin, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : JAZZ
The primary concerns for JAZZ are EPS Growth, Return on Equity, Profit Margin. A P/E of 1921.3x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
JAZZ carries more volatility with a beta of 0.33 — expect wider price swings.
JAZZ is growing revenue faster at 19.1% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (64/100 vs 56/100), backed by strong 29.6% margins and 19.0% revenue growth. JAZZ offers better value entry with a 52.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Jazz Pharmaceuticals PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?